Norwegian University of Science and Technology is a public research university located in the city of Trondheim, Norway. NTNU is the second largest of the eight universities in Norway, and, as its name suggests, has the main national responsibility for higher education in engineering and technology. In addition to engineering and the natural and physical science, the university offers advanced degrees in other academic disciplines ranging from the social science, the arts, medicine, architecture and fine art.The current rector is professor dr.med. Gunnar Bovim. Wikipedia.
Norwegian University of Science and Technology | Date: 2016-10-12
Disclosed herein is a computer-implemented method for simulating a response of a drug, or a combination of drugs, being used for the treatment of a disease, the method comprising a computing device performing the steps of: generating one or more models of cell responses in a biological network of cellular processes, wherein each model is a self-contained logical model that comprises a network topology with nodes, edges between nodes and parameters of the nodes for modelling obtained state data of a plurality of biological signalling entities of one or more diseased cells, wherein generating each model comprises automatically determining logical rules that define at least the parameters of the nodes such that an attractor of the model substantially corresponds to said obtained state data of the plurality of biological signalling entities of one or more diseased cells; for each of the one or more models, simulating the effect of a drug, or a combination of drugs, by determining an output of the generated model when the states of one or more nodes of the model are changed in accordance with the expected effect of the drug, or the combination of drugs, on one or more of said biological signalling entities; and determining a drug, or a combination of drugs, for the treatment of the one or more diseased cells in dependence on the outputs of the one or more models. Advantageously, a fast and inexpensive technique is provided for determining drug(s), or combinations of drugs, for the treatment of the disease.
Nordlandssykehuset Hf, Norwegian University of Science, Technology and University of Oslo | Date: 2014-03-21
The present invention relates to chimeric anti-CD14 antibodies and methods of using the same. In some embodiments, the present invention relates to the use of chimieric anti-CD 14 antibodies in research, diagnostic, and therapeutic applications. In one embodiment, the anti-CD14 antibody has a variable light chain of SEQ ID NO: 1 and a variable heavy chain of SEQ ID NO: 2 (isolated from the hybridoma clone 18D11). In another embodiment, the anti-CD14 antibody has a variable light chain of SEQ ID NO: 3 and a variable heavy chain of SEQ ID NO: 4 (isolated from the hybridoma clone Mil2).
Norwegian University of Science and Technology | Date: 2015-06-15
Disclosed herein is a method of generating a coded data packet in dependence on a plurality of source data packets, the method comprising: determining a plurality of data packets, for generating a coded data packet, from a plurality of source data packets for encoding, wherein each of the plurality of source data packets for encoding comprises the same number of bits; generating a multiplied data packet in dependence on one or more multiplication operations between a multiplication value and bits of one of the determined data packets; and generating a coded data packet in dependence on a combination of the multiplied data packet and one or more of the other of said plurality of determined data packets that have not been multiplied; wherein the one or more multiplication operations are performed as operations in the finite field GF(p); p is greater than 2; the multiplication value is an element of the finite field GF(p); the multiplication value is not 0 or 1; and the combination of data packets is performed by bitwise XOR operations. Advantageously, the coding scheme can be almost as computationally efficient as GF(2) and the likelihood of obtained coded data packets being linearly independent is greatly increased.
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-EJD | Phase: MSCA-ITN-2016 | Award Amount: 3.76M | Year: 2017
Though security is a field of study capable of diverse applications in daily life, security science is a young discipline requiring larger inter-disciplinary effort. ESSENTIAL seeks to develop security science by addressing two of its main problems: the ad-hoc approach to security research and the growing complexity of the security environment. To do so, ESSENTIAL has set itself two main goals: a) to train inter-disciplinary security experts and professionals, to tackle security threats in a systematic manner and b) to increase societal resilience and security by addressing in an interdisciplinary manner 15 research topics, each associated with long-standing problems in the field of security science ranging from modeling security perception and democratizing intelligence to improving security and privacy in data ecosystems. ESSENTIAL will be the first programme of its kind that aims to jointly educate the next generation of interdisciplinary experts in security science, by uniquely exposing the 15 ESRs to: (1) theoretical knowledge and practical expertise in such areas as: (a) the policing and regulation of information-security technology, and (b) the implementation of policies and legal standards within computing and communication systems; (2) real-world environments in law enforcement, intelligence and industry; (3) strong academic guidance offered by highly qualified supervisors and mentors; (4) high tech research infrastructures; and (5) a diversity of interdisciplinary research events, such as workshops, conferences, summer/winter schools. The ESSENTIAL consortium is built upon long-lasting cooperation relations among leading organizations coming from academia, international and national stakeholders and the private sector, many of whom have over 25 years of experience in contributing directly to national, European and UN technology-related policy making.
Agency: European Commission | Branch: H2020 | Program: IA | Phase: LCE-02-2016 | Award Amount: 16.31M | Year: 2017
An inspiration for INVADE are the world-wide agreements on minimisation of human caused effects to climate change and energy efficiency targets set at the European Union with ambitious goals for reduction of greenhouse gas emission and for increase of renewable energy share. To enable a higher share of renewable energy sources to the smart grid and gain a traction in the market place a few critical barriers must be overcome. There is a deficiency of 1) flexibility and battery management systems 2) exploration of ICT solutions based on active end user participation 3) efficient integration of energy storage and transport sector (EVs), 4) novel business models supporting an increasing number of different actors in the grid. INVADE addresses these challenges by proposing to deliver a Cloud based flexibility management system integrated with EVs and batteries empowering energy storage at mobile, distributed and centralised levels to increase renewables share in the smart distribution grid. The project integrates different components: flexibility management system, energy storage technologies, electric vehicles and novel business models. It underpins these components with advanced ICT cloud based technologies to deliver the INVADE platform. The project will integrate the platform with existing infrastructure and systems at pilot sites in Bulgaria, Germany, Spain, Norway and the Netherlands and validate it through mobile, distributed and centralised use cases in the distribution grid in large scale demonstrations. Novel business models and extensive exploitation activities will be able to tread the fine line between maximizing profits for a full chain of stakeholders and optimizing social welfare while contributing to the standardization and regulation policies for the European energy market. A meaningful integration of the transport sector is represented by Norway and the Netherlands pilots with the highest penetration of EVs worldwide.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SC1-PM-04-2016 | Award Amount: 9.71M | Year: 2017
The projects overall aim is to improve the health, development and quality of life of children and adults born very preterm (VPT, < 32 weeks of gestation) or very low birth weight (VLBW, < 1500g) approximately 50 000 births each year in Europe by establishing an ICT platform to integrate, harmonise and exploit the wealth of data from 20 European cohorts of VPT/VLBW children and adults and their families constituted from the early 1980s to the present, together with data from national registries. VPT/VLBW births have higher risks of cerebral palsy, visual and auditory deficits, impaired cognitive ability, psychiatric disorders and social problems than infants born at term and account for more than a third of the health and educational budgets for children. They may also face higher risks of non-communicable disease as they age. There is emerging evidence of reduced mental health, quality of life, partnering, family life and employment chances and wealth in adulthood. The platform will enable stratified sub-group analyses of sociodemographic and clinical characteristics, neonatal complications, and otherwise rare medical conditions that cannot be studied in national population cohorts. The broad temporal, geographic, cultural and health system diversity makes it possible to study the impact of socioeconomic and organisational contexts and determine the generalisability of outcomes for VPT/VLBW populations. The RECAP platform creates a value chain to promote research and innovation using population cohorts, beginning with the integration of VPT/VLBW cohorts to the translation and dissemination of new knowledge. It will be based on a sustainable governance framework, state-of-the art data management and sharing technologies, tools to strengthen research capacity, a hypothesis-driven research agenda and broad stakeholder participation, including researchers, clinicians, educators, policy makers and very preterm children and adults and their families.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SC1-PM-09-2016 | Award Amount: 5.82M | Year: 2017
Tuberculosis (TB) today rivals HIV/AIDS as the leading cause of death from infectious diseases. The number of TB patients has never been higher and the growing proportion of drug-resistant TB is threatening control strategies both in the developing and developed world, Eastern Europe being a particularly worrying point in case. The anTBiotic consortium aims to fuel the long-term TB clinical pipeline while immediately offering new options to clinicians when confronted with multidrug-resistant (MDR)-TB. More specifically, the proposed studies aim to: a) Establish the proof of concept of anti-TB efficacy in humans of a pioneering, first-in-class, low-dose GSK oxaborole clinical drug candidate; b) Identify a combination of -lactam antibiotics suitable for the treatment of MDR TB orally or as a once daily intravenous or intramuscular application and c) Incorporate the best -lactam combination into an explorative salvage regimen for untreatable patients with extensively drug-resistant TB The anti-TB activity in humans will be established in a two-week EBA clinical studies that combine established (CFU, TTP) and new clinical markers (biomarkers, PET/CT). These datasets will help ascertain anti-TB efficacy in humans and generate confidence on their validity in longer-term drug combination trials. A variety of modelling approaches to predict optimal dosing will be used. Finally, we intend to use at least one of these novel anti-TB entities as part of a pioneering, non-controlled clinical trial in highly drug resistant subjects in Europe and South Africa. This final clinical intervention will hopefully be of immediate benefit to drug-resistant patients in the EU and elsewhere in addition to generating a strong precedent for further adoption worldwide.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: FETOPEN-01-2016-2017 | Award Amount: 4.43M | Year: 2017
Current and future technological and societal demands require the transfer of vast amounts of data at speeds currently not available due to a lack of technology operating in the terahertz (THz) gap. TRANSPIRE will develop nano-scale THz-oscillators based on a new class of magnetic materials, which will function in this exact range and meet these demands. This will enable new functionalities with high societal impact, such as enabling remote hospitals, personal and substance security screening, medical spectrometry and imaging, geophysical and atmospheric research. Given the tuneability of their anisotropy, damping and magnetisation, newly discovered low-moment, ultra-high anisotropy field, highly spin-polarised ferrimagnets can enable terahertz technologies by exploiting magnetic resonance. Ferrimagnetic resonance will be excited by spin-transfer torque (STT) acting on the sub-lattice magnetisation, and detected via magnetoresistive effects. STT, so far only demonstrated in ferromagnetic systems, is the basis of all recent scalable magnetic random access memory designs. TRANSPIRE will optimize the materials, tuning their resonant properties and advancing the fundamental understanding of STT in two-sub-lattice systems. The breakthrough objective of a low-cost, compact, reliable, room-temperature terahertz technology has a huge potential, including on-chip and chip-to-chip data links. The natural outcome of the foundational work of TRANSPIRE will be to empower a number of high-potential actors to judge on the viability of spintronic terahertz technology and to be at the forefront of research, thus ensuring future industrial European leadership on the world stage. TRANSPIRE relies on coordinated interdisciplinary research in physics, chemistry, materials science, terahertz design and device engineering to ensure the success of this inherently high-risk endeavour, which can underpin the next wave of the Big Data revolution.
Linder J.,Norwegian University of Science and Technology |
Robinson J.W.A.,University of Cambridge
Nature Physics | Year: 2015
Traditional studies that combine spintronics and superconductivity have mainly focused on the injection of spin-polarized quasiparticles into superconducting materials. However, a complete synergy between superconducting and magnetic orders turns out to be possible through the creation of spin-triplet Cooper pairs, which are generated at carefully engineered superconductor interfaces with ferromagnetic materials. Currently, there is intense activity focused on identifying materials combinations that merge superconductivity and spintronics to enhance device functionality and performance. The results look promising: it has been shown, for example, that superconducting order can greatly enhance central effects in spintronics such as spin injection and magnetoresistance. Here, we review the experimental and theoretical advances in this field and provide an outlook for upcoming challenges in superconducting spintronics. © 2015 Macmillan Publishers Limited. All rights reserved.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: FETOPEN-01-2016-2017 | Award Amount: 3.27M | Year: 2017
This project will investigate the next generation of materials and devices for latent heat thermal energy storage (LHTES) at ultra-high temperatures of up to 2000C, which are well beyond todays maximum operation temperatures of ~1000C. We will synthetize new phase change materials (PCMs) with latent heat in the range of 2-4 MJ/kg (an order of magnitude greater than that of typical salt-based PCMs); we will develop advance thermal insulation and PCM casing designs, along with novel solid-state heat to power conversion technologies able to operate at temperatures up to 2000C. Using these new materials and devices, we aim at realizing the proof of concept of a new kind of extremely compact LHTES device with unprecedented high energy density. The key enabling technologies are: novel PCMs based on the silicon-boron system with ultra-high melting temperature and latent heat, novel refractory lining composites based on carbides, nitrides and oxides for the PCM container walls, advanced thermally insulated PCM casing for ultra-high temperature operation, and novel solid-state heat-to-power converters based on photovoltaic and thermionic effects. In this regard, we will perform the proof of concept of a new kind of hybrid thermionic-photovoltaic converter (TIPV) that has been recently formulated theoretically. TIPV cells combine the ionic and photovoltaic phenomena to convert high temperature heat directly into electricity at very high power rates. The final goal of this project is to demonstrate the proof-of-concept of this idea and kick-starting an emerging research community around this new technological option.